Kostić Svetlana, Tasić Ivan, Stojanović Nikola, Rakočević Jelena, Deljanin Ilić Marina, Đorđević Dragan, Stoičkov Viktor, Tasić Isidora
Institute for Therapy and Rehabilitation "Niška Banja", 18205 Niška Banja, Serbia.
Faculty of Medicine, University of Niš, 18000 Niš, Serbia.
Diagnostics (Basel). 2024 Jul 19;14(14):1569. doi: 10.3390/diagnostics14141569.
Metabolic syndrome (MetSy) is characterized by the presence of obesity, hypertension, altered glucose metabolism, and/or increased non-HDL cholesterol. This study aimed at elucidating the association between obesity with subclinical target organ damage and biochemical parameters included in MetSy pathogenesis.
This study included 130 apparently healthy subjects. Plasma levels of oxidized-LDL-cholesterol (ox-LDL-Chol), nitric oxide (NO) metabolites, inducible NO synthase (iNOS), and plasminogen activator inhibitor-1 (PAI-1) were measured. Non-invasive assessment of liver disease included fatty liver index (FLI) and nonalcoholic fatty liver disease (NAFLD) fibrosis score. Carotid artery plaques were assessed by color Doppler imaging.
A total of 65 patients with MetSy were included in the MetSy group, while 65 without MetSy entered the control group. Ox-LDL-Chol levels were higher in the MetSy group compared to the control group, regardless of obesity. Levels of NO metabolites were similar in obese and non-obese patients with MetSy, but lower than in the control group. Obese patients with MetSy had higher iNOS values compared to non-obese ones, with similar PAI-1 levels. NAFLD was present in all obese patients with MetSy compared to 70% of non-obese subjects. Hypertension, higher values of waist-to-hip ratio, PAI-1, and remnant cholesterol were associated with NAFLD. Finding of asymptomatic carotid plaques was associated with patients' age, hypertension, and higher waist-to-hip ratio.
MetSy and obesity significantly alter the levels of NO metabolites, iNOS, ox-LDL-Chol, and PAI-1. High prevalence of NAFLD in obese patients with MetSy requires active screening and treatment of potential risk factors.
代谢综合征（MetSy）的特征是存在肥胖、高血压、糖代谢改变和/或非高密度脂蛋白胆固醇升高。本研究旨在阐明肥胖与亚临床靶器官损害以及代谢综合征发病机制中所包含的生化参数之间的关联。
本研究纳入了130名表面健康的受试者。测量了血浆中氧化型低密度脂蛋白胆固醇（ox-LDL-Chol）、一氧化氮（NO）代谢产物、诱导型NO合酶（iNOS）和纤溶酶原激活物抑制剂-1（PAI-1）的水平。肝病的非侵入性评估包括脂肪肝指数（FLI）和非酒精性脂肪性肝病（NAFLD）纤维化评分。通过彩色多普勒成像评估颈动脉斑块。
MetSy组共纳入65例代谢综合征患者，而65例无代谢综合征患者进入对照组。无论肥胖情况如何，MetSy组的ox-LDL-Chol水平均高于对照组。肥胖和非肥胖的代谢综合征患者中NO代谢产物水平相似，但低于对照组。与非肥胖的代谢综合征患者相比，肥胖的代谢综合征患者iNOS值更高，PAI-1水平相似。所有肥胖的代谢综合征患者均存在NAFLD，而非肥胖受试者中这一比例为70%。高血压、腰臀比、PAI-1和残余胆固醇的较高值与NAFLD相关。无症状颈动脉斑块的发现与患者年龄、高血压和较高的腰臀比相关。
代谢综合征和肥胖显著改变了NO代谢产物、iNOS、ox-LDL-Chol和PAI-1的水平。肥胖的代谢综合征患者中NAFLD的高患病率需要对潜在危险因素进行积极筛查和治疗。
